Literature DB >> 789031

Combination amphotericin B-rifampin therapy for pulmonary aspergillosis in a leukemic patient.

B Ribner, G T Keusch, B A Hanna, M Perloff.   

Abstract

Pulmonary aspergillosis developed in a 62-year-old man with acute myelogenous leukemia. Therapy with amphotericin B and 5-fluorocytosine was begun. Synergy between amphotericin B and rifampin was demonstrated in vitro, and therapy with firampin replaced 5-fluorocytosine. Progressive clearing of the pulmonary lesion ensued, suggesting in vivo efficacy as well. Further studies of patients utilizing this regimen are warranted.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 789031     DOI： 10.1378/chest.70.5.681

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


  8 in total

1.  In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.

Authors:  C E Hughes; C Harris; J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

Review 2.  Aspergillosis of the CNS in a pediatric liver transplant recipient: case report and review.

Authors:  M Green; E R Wald; A Tzakis; S Todo; T E Starzl
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

Review 3.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

Authors:  A B Morris; R B Brown; M Sands
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

4.  Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents.

Authors:  F Meunier
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

5.  Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy.

Authors:  H Link; G Maschmeyer; P Meyer; W Hiddemann; W Stille; M Helmerking; D Adam
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

Review 6.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

7.  Synergistic action of amphotericin B and rifampin against Rhizopus species.

Authors:  J C Christenson; I Shalit; D F Welch; A Guruswamy; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

8.  Synergism between Medihoney and rifampicin against methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Patrick Müller; Dagmar G Alber; Lynne Turnbull; Ralf C Schlothauer; Dee A Carter; Cynthia B Whitchurch; Elizabeth J Harry
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.